Perspective Therapeutics Q1 EPS Increased by Brookline Cap M

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Research analysts at Brookline Cap M upped their Q1 2026 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a report released on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver now expects that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($0.44). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Cap M also issued estimates for Perspective Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.27) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The business had revenue of $0.04 million during the quarter.

Several other equities research analysts have also commented on the stock. Royal Bank Of Canada decreased their target price on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday. HC Wainwright increased their price target on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, January 30th. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday. Piper Sandler started coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective on the stock. Finally, BTIG Research restated a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat, Perspective Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Trading Down 3.3%

Shares of CATX stock opened at $4.45 on Thursday. The business’s fifty day moving average price is $4.37 and its 200 day moving average price is $3.44. The company has a quick ratio of 8.66, a current ratio of 5.17 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $6.16.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Perspective Therapeutics in the 2nd quarter worth about $61,000. Geode Capital Management LLC grew its stake in Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Perspective Therapeutics by 118.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after acquiring an additional 405,612 shares in the last quarter. Walleye Capital LLC increased its holdings in Perspective Therapeutics by 375.8% during the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after acquiring an additional 148,013 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in Perspective Therapeutics by 44.4% during the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock worth $671,000 after acquiring an additional 60,019 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics News Roundup

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: UBS raised its price target for CATX to $8.00, signaling increased upside from current levels and giving investors a higher valuation reference. UBS Group Raises Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $8.00
• Positive Sentiment: B. Riley Financial analyst says CATX stock price is expected to rise, which can attract momentum buying and support higher valuations. Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Expected to Rise, B. Riley Financial Analyst Says
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on CATX, reinforcing buy-side sentiment from another boutique/specialist analyst. Wedbush Reaffirms “Outperform” Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)
• Positive Sentiment: Brookline Capital Markets materially raised its FY2026 and quarter-by-quarter EPS estimates (still negative EPS, but less severe), suggesting improving expectations for the company’s financial trajectory. This reduces downside risk from prior forecasts. (Market data / analyst note)
• Positive Sentiment: BTIG initiated/maintained a Buy rating on CATX, adding further institutional buy-side support. Perspective Therapeutics (NYSEAMERICAN:CATX) Earns Buy Rating from BTIG Research
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX, which can add short-term pressure and offset some of the positive analyst actions. Royal Bank Of Canada Has Lowered Expectations for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.